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Take home message: Among children in a low low-resource setting in Latin America, younger 
age, an established asthma diagnosis and history of severe asthma attacks in the previous year 
were associated with recurrence of severe asthma attacks, irrespective of biomarkers. 
 
  
ABSTRACT: 
Asthma is a common cause of emergency care attendance in low and middle-income countries 
(LMICs). While few prospective studies of predictors for emergency care attendance have been 
undertaken in high-income countries, none have been done in a LMIC. 
We followed a cohort of 5-15 year olds treated for asthma attacks in Emergency Rooms (ERs) 
of public health facilities in Esmeraldas City, Ecuador. We collected blood and nasal wash 
samples, and did spirometry and Fractional exhaled Nitric Oxide measurements. We explored 
potential predictors for recurrence of severe asthma attacks requiring emergency care over 6 
months follow-up. 
We recruited 283 children of whom 264 (93%) were followed up for at least 6 months or until 
their next asthma attack. Almost half (46%) had a subsequent severe asthma attack requiring 
emergency care. Predictors of recurrence in adjusted analyses were (adj. OR; 95% CI) younger 
age (0.87 per year; 0.79-0.96), previous asthma diagnosis (2.2; 1.2-3.9), number of parenteral 
corticosteroid courses in previous year (1.3; 1.1-1.5), food triggers (2.0; 1.1-3.6), and eczema 
diagnosis (4.2; 1.02-17.6). A parsimonious Cox regression model included the first three 
predictors plus urban residence as a protective factor (adj. HR: 0.69; 0.50-0.95). Laboratory 
and lung function tests did not predict recurrence. 
Factors independently associated with recurrent emergency attendance for asthma attacks 
were identified in a low-resource LMIC setting. This study suggests a simple risk-assessment 
tool could potentialy be created for ERs in similar settings to identify higher risk children on 
whom limited resources might be better focussed. 
 
  
INTRODUCTION 
Severe asthma attacks requiring emergency care, hospital admission or systemic 
corticosteroids[1] are a common source of preventable morbidity in children. Asthma attacks 
are associated with impaired lung function [2], anxiety in patients and families [3], and 
elevated healthcare and family costs [4]. Many asthma attacks are preventable, either by 
avoiding triggers or by appropriate preventive treatment. Inhaled corticosteroids (ICS) reduce 
the probability of asthma attacks by around 40% [5] and can attenuate the decline in lung 
function associated with asthma attacks [2]. Because ICS have associated side-effects[6-8] and 
costs, use should be targeted at those at greater risk of attacks or persistent symptoms, 
especially when resources are limited. Identifying children with a greater risk of asthma attacks 
is crucial for optimization of asthma treatment, particularly in low resource settings where 
underdiagnosis and lack of capacity for long-term management are major problems. 
In most Latin American countries where health resources and specialist follow-up care are 
limited [9,10], children with asthma are mainly seen in emergency rooms (ER) during acute 
attacks [11,12]. The ER represents an opportunity to identify children at higher risk of future 
attacks. Factors that have been previously associated with recurrent asthma attacks requiring 
emergency care in paediatric cohort studies include history of previous ER attendance for 
attacks, younger age, black ethnicity and low socioeconomic status [13-16]. However, these 
studies have been almost exclusively done in North America and did not evaluate potential 
usefulness of biomarkers commonly available in higher income settings [16]. No prospective 
studies investigating emergency room reattendance for asthma from lower income settings 
were identified in a recent systematic review [16]. 
We undertook a prospective cohort study to identify clinical factors and biomarkers associated 
with recurrent severe asthma attacks in children presenting with an asthma attack to regional 
ERs in a limited resource setting in Latin America.  
 
METHODS 
Study population and design 
This prospective cohort study was done in the city of Esmeraldas (population 150,000 of 
mainly Afro-Ecuadorian ethnicity) in the north-western coastal province of Esmeraldas. 
Patients were recruited from the city’s public hospital, Delfina Torres de Concha Hospital 
(DTCH) that offers free attention and treatment, the Instituto Ecuatoriano de Seguro Social 
Esmeralda’s Hospital (IESS) which offers free treatment to those paying national insurance, 
and the three largest public health centres in the city with 24-hour emergency care.  
Children aged 5-15 years treated at emergency departments for asthma attacks (defined as 
bronchodilator-responsive wheeze) were recruited between May 2014 and September 2015. 
Children with other chronic conditions were excluded. Written consent was obtained from the 
child’s caregiver and minor assent from children over 7 years. A total of 283 children were 
recruited. The protocol was approved by the Bioethics Committees of the Liverpool School of 
Tropical Medicine and the Universidad San Francisco de Quito, Quito, Ecuador. 
 
Measurements of exposures and outcomes 
Data were collected in Spanish from the child’s caregiver using a modified version of the 
International Study of Asthma and Allergies in Childhood (ISAAC) Phase II questionnaire [17] 
that has been extensively field-tested[18,19], together with additional questions regarding 
potential risk factors for recurring asthma attacks. A detailed description of variables studied is 
included in online supplementary table S1. The Childhood Asthma Control Test (C-ACT)[20] 
was completed by the child and guardian for children <12 years of age or the Asthma Control 
Test[21] for those ≥12. Weight and height were measured. A blood sample was drawn for 
haematocrit, blood count, and plasma assays. Total and specific IgE (sIgE) for D. pteronyssinus 
and B. tropicalis were measured using the CAP system (Pharmacia Diagnostics) in 86 random 
plasma samples, of which 60 were tested for German cockroach and food mix (egg white, milk, 
cod, wheat, peanut, soy) specific IgE. A positive assay for sIgE was defined as >0.70 kU/l. A 
nasal wash with saline was done to determine the relative proportion of granulocytes 
(eosinophil vs. neutrophils) using a protocol modified from a previous study [22] (see online 
supplementary file for detailed technique). Participants returned 2 weeks after recruitment (or 
up to 3 weeks if during the 2-week appointment they were still taking daily salbutamol or oral 
corticosteroids or had wheezing) for pre and post-bronchodilator spirometry (Microloop 
spirometer, Micro Direct, UK) and Fractional Exhaled Nitric Oxide (FeNO: NObreath, Bedfont 
Scientific, UK). At this time, the Pediatric Asthma Quality of Life Questionnaire (PAQLQ)[23] 
and Newcastle Asthma Knowledge Questionnaire (NAKQ)[24,25] were completed. Asthma 
severity was classified using the Ecuadorian Asthma Consensus 2011[26] which closely follows 
GINA 2008[27] and Spanish 2009 asthma guidelines (GEMA 2009)[28]. Participants were 
offered inhaled beta2-agonists as relievers with or without corticosteroids for long-term 
treatment in accordance with these guidelines. They were also provided with a standardised 
short education on asthma, recommendations for future asthma attacks, and written asthma 
action plans. 
Each participant was followed up with twice-monthly telephone calls asking about asthma 
attacks (number, severity, duration and treatment received) and told to contact the study 
team immediately following an attack. A severe asthma attack was defined as an acute 
exacerbation of respiratory symptoms (difficulty breathing and wheezing that improved with 
bronchodilators) requiring either i) urgent care at an ER or ii) unscheduled medical visit with 
prescription of systemic corticosteroids (for at least 3 days if oral)[1]. Hospital and health 
centres’ records were checked twice-weekly to record unscheduled visits for attacks. 
Statistical analysis 
The primary outcome was recurrence of an asthma attack requiring emergency care and 
occurring between 2 weeks and 6 months after the index attack. Only the first recurrence was 
considered in the analysis among those with more than one attack during follow-up. Only 
variables measured at baseline were studied as risk factors. Continuous variables were 
compared using Student’s t or the Mann-Whitney U tests, as appropriate. Categorical variables 
were compared using Fisher’s exact test.  Multivariable logistic regression was used to 
evaluate the effects of multiple risk factors for emergency care re-attendance on risk of 
recurrence of asthma attacks. Only children followed-up until their first asthma attack 
recurrence or for a minimum of 6 months exacerbation-free were included in this analysis. A 
time-to-event analysis was done using a multivariable Cox proportional hazard model, 
including all children that completed at least 2 weeks follow-up. Collett’s method[29] of 
variable selection was used with a P value threshold of 0.2, and confounding and interactions 
between variables were assessed. The parsimonious logistic and Cox models were selected 
based on explained variation (R2). The proportional hazards assumption required by the Cox 
model was tested via the inclusion of time-dependent variables. The assumption was valid for 
all included variables.  
The predictive ability of the models was evaluated by estimating the area under the Receiver 
Operating Characteristics curve (ROC)[30] and its 95% confidence interval, with 0.5 indicating a 
model with no discriminating power and 1.0 a perfectly discriminating model[31]. Internal 
validity was then assessed by bootstrapping using 200 random bootstrap samples with 
replacement, to evaluate potential bias (over- or under-fitting). Optimism in regression 
coefficients due to overfitting was estimated by measuring the difference between the 
model’s c-statistic (apparent c-statistic) and the c-statistic computed by nonparametric 
bootstrap resampling (internal bootstrap validation c-statistic)[32].  
Statistical analyses were done using STATA 13.1 with significance set at P < 0.05. Details of 
sample size calculations and missing data strategy are provided in online supplementary 
methods. 
 
RESULTS 
Of the 283 children recruited, thirteen (4.6%) were lost to follow-up after the initial visit, and 
264 (93%) were followed up until their next asthma attack or a minimum of 6 months 
exacerbation-free. Of these, 121 (46%) had at least one subsequent asthma attack requiring 
emergency care during the first 6 months of follow-up (figure 1). The median follow-up time 
was 408 days (IQR: 265-541 days, range 44-697 days) and the median time to a subsequent 
asthma exacerbation was 91 days (IQR:  39-178 days). Figure 2 shows time to first recurrence 
of a severe asthma attack. 
 
Table 1 and 2 show characteristics for the 264 children completing 6 months follow-up or until 
first asthma attack recurrence, stratified by readmission status at 6-months follow-up. 
Available data for each variable are shown in the online supplementary table S1. Data for 
allergy and inflammatory markers and lung function are shown in figure 3. Thirty nine percent 
(107/272) of all children had blood eosinophilia (>500cells/µl) and 72% had nasal eosinophilia 
(>5%) [33]. Median FeNO for the whole sample was 33ppb (IQR: 3-79).  Median predicted FEV1 
in 223 children who underwent spirometry was 97% (IQR: 86-107) of whom 30 (13%) had 
values below the lower limit of normal. Median Pre-FEV1/FVC ratio was 91% (IQR: 85-97), 
median FEV1 increase after inhaled bronchodilator was 6.4% (IQR: 2-14) and 109 (49%) had a 
positive bronchodilator response (increase in FEV1 >12%). IgE was measured in a random 
sample of 86 participants: total IgE (median, 770 kU/l, IQR: 329-1376), and mite (D. 
pteronyssinus and B. tropicalis) IgE (81% positive). Of the 60 samples tested for specific IgE for 
cockroach and food allergens, 82% were positive for any allergen. 
  
Table 1: Sociodemographic characteristics, personal and family history of 264 participants 
followed-up for 6 months or until first asthma attack recurrence, stratified by recurrence 
status at 6 months 
 
 
Total Cohort 
(N=264) 
Second asthma attack within 6 months 
Yes (N=121) No (N=143) P 
Sociodemographic Characteristics     
Age (years) (median, IQR) 8 (6-11) 7 (5-10) 9 (7-11) <0.001 
Sex male (%) 59 60 59 0.900 
Ethnicity  
(%) 
Afro-Ecuadorian 54 52 55 
0.963 
Mestizo 43 45 42 
White 2 2 1 
Other 2 2 2 
BMI (kg/m2) (median, IQR) 
16.6  
(15.1-19.4) 
16.4  
(15.0-19.2) 
16.9  
(15.1-19.7) 
0.265 
At least one sibling (%) 90 89 91 0.547 
No. of years study by mother + No. of 
years by father (median, IQR) 
24 (18-28) 24 (18-28) 24 (19-29) 0.304 
Pets at home (%) 43 45 42 0.708 
Second hand smoke exposure (%) 18 17 21 0.474 
Humid household (%) 47 4 51 0.137 
Urban setting (%) 66 60 70 0.094 
Intense traffic near house (%) 30 30 30 1.000 
Monthly household income (USD) 
(median, IQR) 
400 (255-700) 400 (260-700) 350 (250-700) 0.981 
Personal and Family History     
Early life respiratory illness (%) 49 59 40 0.013 
Allergic rhinitis ever (%) 72 74 70 0.490 
Allergic rhinitis diagnosis (%) 21 20 21 0.878 
Eczema ever (%) 13 14 12 0.713 
Eczema diagnosis (%) 4 7 2 0.119 
Paternal/maternal asthma (%) 46 53 41 0.175 
Paternal/maternal 
asthma/rhinitis/eczema (%) 
68 70 66 0.788 
IQR: Interquartile range; BMI: Body Mass Index; USD: US dollars. 
Bold: statistically significant differences (p<0.05) 
 
 
 
 
 
 
 
Table 2: Asthma characteristics* of 264 participants followed for 6 months or until first asthma 
attack recurrence, stratified by readmission status at 6-months. 
 
Total Cohort 
(N=264) 
Second asthma attack within 6 months 
Yes (N=121) No (N=143) P 
Wheezing ever (%) 94 98 90 0.021 
Wheezing last 12m (%) 87 93 81 0.003 
No. attacks last 12m (median, IQR) 3 (2-6) 5 (2-6) 3 (1-5) <0.001 
Days since last attack (median, IQR) 60 (30-120) 60 (30-120) 60 (30-150) 0.120 
Wheezing at 
night last 12m 
(%) 
Never 19 16 21 
0.424 
<1 night per week 1 2 0.7 
≥1 night per week 14 17 11 
Only during attacks 66 66 67 
Severe attack last 12m (%) 36 44 30 0.014 
Wheezing 
with exercise 
(%) 
No 36 30 41 
0.188 Yes 40 44 37 
Only during attacks 24 27 23 
Previous asthma diagnosis (%) 64 77 54 <0.001 
Number of triggers (median, IQR) 4 (2-6) 4 (3-6) 4 (2-5) 0.117 
Food as trigger (%) 37 46 29 0.006 
Doctor visit 
for acute 
asthma last 
12m (%) 
None 15 8 21 
<0.001 
1-3 49 46 53 
4-12 27 32 23 
>12 8 14 3 
Doctor visit 
for asthma 
control last 
12m (%) 
None 68 65 71 
0.592 
1-3 24 26 23 
4-12 7 8 7 
>12 0.4 0.8 0 
ICS treatment (%) 2 0.9 3 0.374 
ER visit last 12m for asthma (%) 76 79 74 0.388 
No. ER asthma visits last 12m (median, 
IQR) 
2 (1-4) 3 (1-6) 2 (0-3) 0.006 
No. IV/IM CS courses last 12m for 
asthma (median, IQR) 
0 (0-1) 1 (0-3) 0 (0-1) <0.001 
Ever admitted for asthma (%) 25 34 18 0.004 
Admitted for asthma last 12m (%) 8 12 4 0.034 
Ever admitted to ICU for asthma (%) 10 13 7 0.102 
IQR: Interquartile range; ICS: Inhaled corticosteroids; ER: emergency room; IV/IM: intravenous or 
intramuscular; CS: corticosteroids; ICU: Intensive Care Unit; 12m: 12 months.  * All the variables were 
measured at baseline, at the moment of the index asthma attack. 
Bold: statistically significant differences (p<0.05) 
 
 
 
 
In univariable analyses (tables 1 and 2), risk factors for recurrence were younger age, early life 
severe respiratory illness, food triggers, previous asthma diagnosis, number and severity of 
asthma attacks over the previous year, and lower haemoglobin levels (recurrence, mean (SD) 
12.9 (0.87) vs. no recurrence, 13.1 (0.84), p=0.032). There were no differences in laboratory or 
lung function parameters (figure 3). Positivity for IgE specific to any allergen did not vary by 
recurrence status (recurrence, 33/42 [79%] vs non-recurrence, 37/44 [84%]). The parents of 
children with recurrence had less specific asthma knowledge (NAKQ score) (OR: 0.91 per 1 
point, 95% CI: 0.85-0.98) and children had lower PAQLQ emotional domain (OR: 0.72 per 1 
point, 95% CI: 0.55-0.94) scores (online supplementary table S2). No differences were seen 
between the two groups for asthma control (ACT and C-ACT scores) or PAQLQ total, symptoms 
or activity scores (online supplementary table S2). Further results concerning food triggers for 
asthma attacks are included in the Supplementary files.  
The multivariable logistic regression model for risk of severe asthma attack recurrence showed 
independent risk factors to be younger age, a previous asthma diagnosis, food triggers, 
number of parenteral corticosteroid courses for acute asthma in the previous 12 months, and 
previous eczema diagnosis (table 3). The area under curve (AUC) of the model was 0.73 (95% 
CI: 0.67-0.79) (c-statistic) and the model explained 13% of variation. After internal validation 
(bootstrapping), AUC reduced to 0.72 and R2 to 14.1%, indicating little overfitting of regression 
coefficients. 
Table 3. Multivariable logistic regression for risk of ER re-attendance for severe asthma attacks 
during 6 months follow-up. (N=264) 
 
Crude OR 95% CI P value 
Adjusted 
OR* 
95% CI P value 
Age 0.87 0.79-0.95 0.001 0.87 0.79-0.96 0.006 
Previous asthma 
diagnosis 
2.78 1.62-4.76 <0.001 2.17 1.19-3.94 0.011 
No. IV/IM  CS courses 
during last 12m  
1.36 1.15-1.61 <0.001 1.28 1.08-1.53 0.006 
Food as trigger 2.11 1.25-3.55 0.005 1.99 1.11-3.55 0.020 
Eczema diagnosis 3.26 0.84-12.6 0.086 4.22 
1.02-
17.54 
0.048 
*: Adjusted Odds Ratios were adjusted for all other variables in the model. OR: odds ratio, CI: 
confidence interval; IV: intravenous; IM: intramuscular; CS: corticosteroids. 
Table 4 shows the results of multivariable analysis for time to asthma attack recurrence. All 
children with at least 2 weeks of follow-up were included in the analysis (N= 270). Children of 
younger age, with an existing asthma diagnosis, greater number of parenteral corticosteroid 
courses for acute asthma in the previous 12 months and not living in an urban setting, showed 
a higher rate of recurrent asthma attacks requiring emergency care. The AUC of the model was 
0.65 (95% CI: 0.60-0.70) (c-statistic) and overfitting of the model was estimated as <1% after 
bootstrapping. 
Table 4. Multivariable Cox regression model for ER re-attendance for severe asthma attacks. 
(N = 270) 
 
Crude HR 95% CI 
P 
value 
Adjusted 
HR* 
95% CI 
P 
value 
Age 0.92 0.87-0.97 0.002 0.93 0.88-0.98 0.009 
Previous asthma 
diagnosis 
1.78 1.26-2.53 0.001 1.66 1.15-2.39 0.007 
No. IV/IM  CS courses 
during last 12m  
1.17 1.10-1.24 <0.001 1.13 1.06-1.20 <0.001 
Urban residence 0.65 0.47-0.89 0.007 0.69 0.50-0.95 0.023 
*: Adjusted Hazard Ratios were adjusted for all other variables in the model. HR: hazard ratio, 
CI: confidence interval; IV: intravenous; IM: intramuscular; CS: corticosteroids. 
 
 
DISCUSSION  
We have identified independent predictors for emergency care re-attendance for severe 
asthma attacks among asthmatic children in a low resource setting in a tropical region of 
coastal Ecuador, the first such prospective study done to our knowledge in an LMIC setting 
[16]. Having a previous severe asthma attack was the most reliable predictor of future risk: 
each acute parenteral corticosteroid course received during the previous year for acute 
asthma increased the odds of a subsequent severe attack by a factor of 1.28. Other factors 
associated with risk of attack or time to next attack were similar including younger age (both), 
an existing asthma (both) or eczema (risk of recurrence) diagnosis, food triggers (risk of 
recurrence), and rural residency (time to recurrence). We were unable to identify a biomarker 
that could usefully predict future risk of severe attacks. 
 
Comparison with previous studies and implications 
The recurrence rate of asthma attacks over 6 months observed (46%) was higher than 
reported in similar studies from UK (37-38%) [34], or US (12-17%) [35], although consistent 
with our previous findings in this setting [11]. This and previous studies have identified a 
history of severe asthma attacks during the preceding year as a predictor for future asthma 
attacks [16]. Other predictors identified in univariate analysis were previous ER attendances, 
number of parenteral corticosteroid courses, and unscheduled contacts for acute asthma. 
However, the number of parenteral corticosteroid courses was the only predictor among these 
associated with asthma attack recurrence in the multivariable model, probably because of the 
specific characteristics of our study setting (low rates of oral corticosteroid prescriptions and 
variable degree of severity of attacks).  
Among sociodemographic characteristics, younger children had a greater risk of subsequent 
asthma attacks, as observed previously in studies done in high-income countries [13,14]. One 
possible explanation is that younger children suffer more from upper respiratory viral 
infections, such as rhinovirus, an important trigger for asthma attacks [36]. Children living in 
the City of Esmeraldas had a lower risk of subsequent asthma attacks compared to those from 
the surrounding rural area, a finding which has not been described previously. Distance to the 
emergency care facilities (located in the city) could have biased the results with only children 
with more severe asthma traveling from rural areas to receive urgent medical attention. The 
association remained after controlling for variables such as educational level of parents and 
socioeconomic factors that have been associated with the risk of asthma attacks [14]. Two 
relevant characteristics that have been previously identified as risk factors for repeated 
asthma attacks did not predict future events in our study: low socioeconomic status (SES) and 
African ethnicity [14,15]. The population in which we worked in Esmeraldas was from poor 
neighbourhoods with a probable high degree of African genetic admixture resulting in a 
relatively homogeneous cohort and perhaps reducing power to identify such factors as 
predictors. A recent study showed that the association between black ethnicity and paediatric 
asthma readmissions was strongly confounded by socioeconomic factors [37], possibly 
explaining why Afro-Ecuadorian ethnicity was not a predictor in our study. Further studies in 
similar LMICs are necessary to clarify the respective roles of SES and ethnicity as determinants 
of asthma attack risk. 
Asthma in the presence of atopy is associated with other allergic diseases including eczema 
and rhinoconjunctivitis. Children with concomitant allergic diseases may have a higher risk of 
future asthma attacks[38], as observed here for children with a previous eczema diagnosis. 
Eczema has been associated with poor asthma control among children in urban Brazil [38]. 
Individuals with allergic asthma appear to be particularly susceptible to virus-induced 
exacerbations [39], and suppression of allergic mediators reduces virally-mediated attacks 
[40]. However, in our study we did not observe associations between allergy markers (blood 
and nasal eosinophilia, and FeNO) or allergic sensitisation (specific IgE) and risk of asthma 
attack recurrence. Further studies are necessary to better understand the nature of this 
association.  
Similarly, there was a greater risk of repeated severe asthma attacks among children 
describing food as a trigger (food allergies, colorants or cold foods). A previous population-
based study from the UK has shown an association between food-induced wheeze in children 
and more frequent attacks of wheeze and healthcare use [41]. However, the mechanisms 
involved in food-induced asthma are not well understood and are not solely immunological, 
making it difficult to diagnose [42]. This was observed in our cohort, where there was no 
association between reported food triggers and a positive IgE to food extracts. Similarly, most 
children reported cold drinks/foods (physical agents) as the triggers of their food-induced 
asthma. 
Predictors of recurrent asthma attacks could be combined into a risk assessment tool to 
identify children with good symptom control but at high risk of attacks, a group representing 
half of those in our study. To be able to reduce the risk in these children, a complete asthma 
management package would need to be implemented: supply of free medications, 
individualised asthma action plan, training for inhaler technique, close monitoring of 
adherence, and control of co-morbidities and modifiable life-style and environmental risk 
factors. 
Strengths and limitations 
Our study had a number of limitations. First, because all children were treated in accordance 
with local guidelines, the fact that this cohort of asthmatic children were followed-up, 
educated about their asthma and provided a written asthma action plan, likely modified their 
outcomes through improved asthma knowledge, adherence to treatment, and management of 
attacks. Second, although we initially aimed to start children on ICS following the Ecuadorian 
guidelines, the large number of children recruited and limited human resources available 
meant it was not possible to monitor the children and their adherence as closely as we would 
have liked. Third, the study population has certain characteristics (including ethnicity, 
socioeconomic status, asthma knowledge, low proportion of ICS use) that may differ from 
other Latin American settings and limit generalizability. Although attendance at ERs for 
treatment of attacks is part of the definition of a severe asthma attack according to 
ATS/ERS[1]. However, the objective of the study was to identify predictors in a real world 
setting to facilitate working towards a risk-assessment tool that can be applied in ERs for any 
patient presenting with bronchodilator-responsive wheeze. Strengths of this study were 
adequate power to identify potential predictors and a high follow-up rate. The comprehensive 
questionnaire, inflammatory markers and lung function measurements were designed to 
explore a broad range of potential risk factors for  asthma attack recurrence. By including all 
bronchodilator-responsive wheeze irrespective of previous asthma diagnosis or lung function 
parameters, this relatively non-selective sample represented more closely patients with real-
life asthma attending emergency rooms.  
Conclusion 
In conclusion, we did a prospective study of children presenting with asthma attacks to ERs in a 
resource-poor setting in Ecuador and identified predictors of reattendance with attacks and 
time to next attack. Approximately half of the recruited asthmatic children suffered a 
subsequent asthma attack within six months of follow-up. Several predictors were identified 
including a previous asthma diagnosis and an asthma attack during the previous year requiring 
systemic corticosteroids. A combination of these predictors could be used as a simple risk-
assessment tool in ERs to identify asthmatic children at a higher risk of recurrent attacks. Such 
a tool would be extremely useful in LMICs where limited resources should be targeted towards 
those most in need of continuing support and treatment. Further studies are now required to 
validate our findings in different low-resource settings. 
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Figure 1: Recruitment and follow-up of participants 
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Figure 2: Kaplan-Meier curve of time to first recurrence of severe asthma attacks. 
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Figure 3:  Allergy and inflammatory markers, and lung function of participants who had 
recurrent severe attacks (readmitted) or not (not readmitted) at 6 months follow-up. P values 
represent inter-group differences using Mann-Whitney U-tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FeNO: Fraction of exhaled Nitric Oxide; FEV1: Forced Expiratory Volume 1st second; FVC: Forced Vital 
Capacity; Pre: pre-bronchodilator; Post: post-bronchodilator 
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SUPPLEMENTARY FILES 
Supplementary Methods 
 
Nasal wash procedure 
Obtaining nasal wash sample: We atomize 2ml of warm (37°C) phosphate-buffered saline 
(PBS) solution into the child’s nostril using a MAD Nasal® atomizer during breath-holding. The 
child is sitting, leaning slightly forward with the head bent slightly forward while holding a 15 
mL centrifuge tube into which is placed the neck of a glass funnel (10-15 ml diameter). The 
funnel is placed below the nose while we atomize slowly the PBS aerosol into the nostril, 
ensuring that the child holds their breath. Once the syringe is emptied and removed from the 
nostril, the child blows strongly through the nose into the funnel while the opposite nostril is 
occluded. This same procedure is repeated in the other nostril and then we wash the funnel 
with 2ml of PBS solution before removing the 15ml centrifuge tube. 
 
Processing of nasal wash sample: After shaking the sample gently on a mixer for 15 minutes, 
we centrifuge at 6000 RPM for 10 minutes. We then store some samples at -80°C and discard 
the remaining supernatant fluid. We place 250μl of pellet into two Cytospin funnels (125μl 
each) and centrifuge at 700 RPM for 4 minutes (Rotofix cytocentrifuge). We dry and stain 
slides with Wrights for direct observation under the microscope. 
 
Spirometry estimations 
The percentage of predicted spirometry values for age and height were estimated using Global 
Lung Initiative standards [1] and the FEV1 post-bronchodilator improvement was calculated as: 
(Post FEV1 - Pre FEV1 / Pre FEV1) x 100%. 
 
Indications for starting inhaled corticosteroids (ICS) 
The most updated Ecuadorian guidelines that we applied are based on the GINA 2008[2] and 
Spanish GEMA 2009[3] guidelines. They recommend controller ICS in children with persistent 
asthma or frequent episodic asthma (not more than 1 exacerbation every 5-6 weeks, with a 
maximum of 6-8 exacerbations per year and without symptoms between the exacerbations). 
 
Statistical analysis:  
Sample size estimation 
We calculated that a cohort of 250 children with a severe asthma attack would provide 80% 
power to detect factors that reduce the proportion of children re-attending the emergency 
room within 6 months from 50% to 31.4% (hazard ratio of ≥1.46), and 90% power to detect 
factors that reduce the proportion of children re-attending emergency room within 1 year 
from 50% to 33.9% (hazard ratio of ≥1.37). The expected proportion of children suffering a 
subsequent asthma attack requiring emergency care was estimated to be 50% over the 
following 6 months, based on our previous findings in this same setting[4]. 
Missing data strategy 
To investigate the effect of missing values for variables with greater than 5% missing data, we 
performed a sensitivity analysis using the “ice”[5] procedure for multiple imputation in Stata 
13.1.  The “mim” procedure in Stata[6] was then used to average the estimates of results 
across the 20 imputed data sets created, according to Rubin's rules[7]. The imputation models 
included all variables selected, the outcome of interest, and the Nelson Aalen estimator of the 
cumulative baseline hazard [8]. There was no difference in the final logistic regression and Cox 
regression multivariable models obtained when using the multiple imputation dataset 
compared to the original dataset (data not shown). 
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Supplementary Results 
With respect to food triggers, of the 93 children who reported food-induced asthma attacks, 
70 reported cold drink or foods as triggers, 28 reported specific foods (milk, nuts, etc.), 5 
reported both, and 2 did not specify the food trigger. The most common specific food triggers 
reported were artificial drinks and food colorants (both reported in 7 children). Allergen 
specific IgE for food mix was measured in a random sample of 59 children, with a positive 
result in 25 (42%) of them. There was no association between a positive food mix IgE and 
recurrence (OR: 1.08; 95% CI: 0.39-3.04). There was also no association between having 
reported a food trigger for asthma attacks and having a positive food mix IgE result (OR: 0.77; 
95% CI:0.26-2.31). 
Table S1: Exposures studied as potential predictors of recurrent asthma attacks, and available 
data out of 270 children that completed at least 2 weeks of follow-up (included in Cox 
regression analysis). 
 
Exposure / predictor Available data (N) Method 
Demographics   
    - Age 270 Questionnaire 
    - Sex 270 Questionnaire 
    - Ethnicity 266 Questionnaire 
    - Siblings 269 Questionnaire 
    - Household location 268 Questionnaire 
    - Overcrowding 269 Questionnaire 
    - Monthly household income 248 Questionnaire 
    - Parental level of education 266 Questionnaire 
Personal history   
     - Gestational age  261 Questionnaire 
    - Birthweight 126 Questionnaire 
    - Breastfeeding 266 Questionnaire 
    - Bronchiolitis/pneumonia as infant 261 Questionnaire 
Asthma history   
    - Wheezing ever 267 Questionnaire 
    - Wheezing last 12m 266 Questionnaire 
    - Doctor’s asthma diagnosis 266 Questionnaire 
    - Date last asthma attack 228 Questionnaire 
    - Number of severe exacerbations last year 265 Questionnaire 
    - ER attendance last year 268 Questionnaire 
    - Number of ER attendance/s last year 267 Questionnaire 
    - Hospitalization/s last year / ever 268 Questionnaire 
    - Admitted to ICU ever 267 Questionnaire 
Asthma treatment previous year   
    - Inhaled corticosteroids 266 Questionnaire 
    - Leukotriene inhibitors 266 Questionnaire 
    - Inhaled/nebulised SABA 266 Questionnaire 
    - No. oral corticosteroids courses 264 Questionnaire 
    - No. parenteral corticosteroids courses 264 Questionnaire 
Asthma symptoms   
    - Asthma control 267 C-ACT; ACT 
    - Quality of life 219 PAQLQ 
    - Triggers (number and specific triggers) 165 Questionnaire 
    - Total time last year with symptoms 268 Questionnaire 
    - Nocturnal symptoms 267 Questionnaire 
    - Symptoms with exercise 260 Questionnaire 
    - Pulmonary function 227 Lung function 
Asthma knowledge   
    - Poor asthma knowledge 253 NAKQ score 
    - Asthma education sessions 269 Questionnaire 
Family history   
    - Maternal rhinitis/asthma/eczema 261 Questionnaire 
    - Paternal rhinitis/asthma/eczema 259 Questionnaire 
Co-morbidities   
    - Allergic rhinitis (Doctor’s diagnosis) 267 Questionnaire 
    - Eczema (Doctor’s diagnosis) 268 Questionnaire 
    - Obesity 249 BMI (weight and 
height)  
   
Environmental exposures 
    - Air pollution at home area 269 Questionnaire 
    - Tobacco exposure at home 268 Questionnaire 
    - Humid household 268 Questionnaire 
    - Mould in household 269 Questionnaire 
    - Carpets in household 269 Questionnaire 
    - Pets 268 Questionnaire 
Inflammatory markers   
    - Blood eosinophilia 261 Blood sample 
    - Nasal eosinophilia 157 Nasal wash 
    - Fraction of exhaled nitric oxide 229 FeNO measurement 
BMI: Body Mass Index; C-ACT: Childhood Asthma Control Test; ACT: Asthma Control Test; NAKQ: 
Newcastle Asthma Knowledge Questionnaire; PAQLQ: Pediatric Asthma Quality of Life Questionnaire; 
FeNO: Fraction of exhaled nitric oxide. 
 
 
 
 
Table S2: Asthma control, asthma knowledge and quality of life of 264 participants followed up 
for 6 months or until first asthma attack recurrence, stratified by readmission status at 6 
months. 
 Total Cohort 
(N=264) 
Second asthma attack within 6 months 
Yes (N=121) No (N=143) P 
C-ACT score (mean, SD) 16.0 (3.75) 15.4 (4.05) 16.5 (3.41) 0.077 
ACT score (median, IQR) 16.0 (13-18) 16.0 (14-18) 15.5 (13-18) 0.936 
NAKQ score (median, IQR) 18 (16-20) 17 (15-20) 18 (16-21) 0.041 
PAQLQ  total score (median, IQR) 3.5 (3.0-4.0) 3.5 (2.9-4.0) 3.5 (3.0-4.2) 0.275 
PAQLQ symptom score (median, IQR) 3.5 (2.8-4.1) 3.6 (2.8-4.0) 3.5 (2.8-4.2) 0.479 
PAQLQ activity score (median, IQR) 3.4 (2.6-4.0) 3.4 (2.6-4.0) 3.4 (2.6-4.2) 0.525 
PAQLQ emotional score (median, IQR) 3.7 (3.1-4.5) 3.5 (3.0-4.2) 3.9 (3.2-4.6) 0.030 
IQR: Interquartile range; C-ACT: Childhood Asthma Control Test; ACT: Asthma Control Test; NAKQ: 
Newcastle Asthma Knowledge Questionnaire; PAQLQ: Pediatric Asthma Quality of Life Questionnaire. 
Bold: statistically significant differences (p<0.05) 
 
 
 
 
 
 
